focus -WSS

focus

author：explore 2025-10-01 02:27:57 - browse：6

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： CMS got Medicare Advantage quality rating wrong, judge rules

WSS

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Senators tussle over abortion against the backdrop of a presidential campaign

Readout LOUD podcast: How biotech is using artificial intelligence

Medicare Advantage proposed rates disappoint insurers

Eli Lilly’s Zepbound improved liver scarring in mid

Finland to offer bird flu vaccine to select groups of people, a possible global first

focus

focus

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

PhRMA lawsuit over Medicare drug price negotiation tossed

Walensky prepares to leave CDC — and Congress — behind

For Medicare Advantage, Democrats want stronger protections around AI

State Dept. review finds Biden bears some blame for Afghanistan failures

An outdated Medicare rule harms dementia patients with anxiety

Malaria cases in Florida and Texas: Here’s what you need to know

Doctors' information doesn't help them choose wisely when sick

State Dept. review finds Biden bears some blame for Afghanistan failures

KalVista pill reduced swelling 'attacks' caused by genetic disease

focus

Readout LOUD podcast: How biotech is using artificial intelligence

A disappointing year of Humira biosimilars

Why did Pfizer dish out millions for a Super Bowl ad?

To avoid data mishandling cases, universities eye AI and other tools

Gilead might be held responsible for not developing a drug

Biden report: The neurospychology of memory and aging

focus

hotspot

explore

knowledge